Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Feb;30(1):1-17.
doi: 10.1016/j.ctrv.2003.10.002.

Epidermal Growth Factor Receptor: A Promising Target in Solid Tumours


Epidermal Growth Factor Receptor: A Promising Target in Solid Tumours

Janessa J Laskin et al. Cancer Treat Rev. .


The epidermal growth factor receptor (EGFR) is expressed in a wide variety of solid tumours. It has been demonstrated that the EGFR-associated signaling pathway plays an important role in carcinogenesis and cancer progression. In the new therapeutic paradigm of molecular-targeted cancer therapy, interference with intracellular signaling cascades is an appealing treatment approach. Inhibitory strategies under study include monoclonal antibodies, tyrosine kinase inhibitors, EGFR-ligand conjugates, EGFR immunoconjugates, and antisense oligonucleotides. Many of these strategies have demonstrated efficacy against EGFR-expressing tumour cells in preclinical studies, prompting a large number of clinical trials. In particular, clinical studies using monoclonal antibody blockade and EGFR tyrosine kinase inhibitors have suggested that EGFR blockade is a well-tolerated and effective treatment strategy; however, more trials are needed to precisely define how these agents will fit into modern cancer care.

Similar articles

See all similar articles

Cited by 53 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources